Nearly one-third of people living with HIV (PLHIV) and taking HAART develop lipodystrophy in Africa. This article aims to describe how they perceive these disorders and the determinants of these perceptions. It is based on a qualitative study using interviews conducted with 20 patients with clinical lipodystrophy in Dakar, Senegal. Not all of the i...
Taverne, BernardDesclaux, AliceDelaporte, EricNdoye, I.
Fin 2013, 11 millions de PVVIH recevaient des ARV en Afrique ; la mise en application de la recommandation de l’OMS de traiter plus précocement (à partir de 500 CD4/mm3) devrait encore accroitre cet effectif. Actuellement, les deux tiers des patients en Afrique reçoivent leur traitement depuis moins de 5 ans, moins de 10 % sont traités depuis 8 ans...
BACKGROUND : Shortening the course of treatment for tuberculosis would be a major improvement for case management and disease control. This phase 3 trial assessed the efficacy and safety of a 4-month gatifloxacin-containing regimen for treating rifampin-sensitive pulmonary tuberculosis. METHODS : We conducted a noninferiority, randomized, open-labe...
Nearly one-third of people living with HIV (PLHIV) and taking HAART develop lipodystrophy in Africa. This article aims to describe how they perceive these disorders and the determinants of these perceptions. It is based on a qualitative study using interviews conducted with 20 patients with clinical lipodystrophy in Dakar, Senegal. Not all of the i...
Nearly one-third of people living with HIV (PLHIV) and taking HAART develop lipodystrophy in Africa. This article aims to describe how they perceive these disorders and the determinants of these perceptions. It is based on a qualitative study using interviews conducted with 20 patients with clinical lipodystrophy in Dakar, Senegal. Not all of the i...